These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9191957)

  • 1. Novel and selective partial agonists of 5-HT3 receptors. 2. Synthesis and biological evaluation of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines.
    Prunier H; Rault S; Lancelot JC; Robba M; Renard P; Delagrange P; Pfeiffer B; Caignard DH; Misslin R; Guardiola-Lemaitre B; Hamon M
    J Med Chem; 1997 Jun; 40(12):1808-19. PubMed ID: 9191957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel selective and partial agonists of 5-HT3 receptors. Part 1. Synthesis and biological evaluation of piperazinopyrrolothienopyrazines.
    Rault S; Lancelot JC; Prunier H; Robba M; Renard P; Delagrange P; Pfeiffer B; Caignard DH; Guardiola-Lemaitre B; Hamon M
    J Med Chem; 1996 May; 39(10):2068-80. PubMed ID: 8642566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
    J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
    J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
    Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
    Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
    J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure-activity relationship studies of spiro[pyrrolidine- and piperidine-2,3'(2'H)-benzopyrans].
    Comoy C; Marot C; Podona T; Baudin ML; Morin-Allory L; Guillaumet G; Pfeiffer B; Caignard DH; Renard P; Rettori MC; Adam G; Guardiola-Lemaitre B
    J Med Chem; 1996 Oct; 39(21):4285-98. PubMed ID: 8863806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
    Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
    J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
    J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors.
    Dukat M; Abdel-Rahman AA; Ismaiel AM; Ingher S; Teitler M; Gyermek L; Glennon RA
    J Med Chem; 1996 Sep; 39(20):4017-26. PubMed ID: 8831767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
    J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure.
    Campiani G; Cappelli A; Nacci V; Anzini M; Vomero S; Hamon M; Cagnotto A; Fracasso C; Uboldi C; Caccia S; Consolo S; Mennini T
    J Med Chem; 1997 Oct; 40(22):3670-8. PubMed ID: 9357534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
    Sato Y; Yamada M; Yoshida S; Soneda T; Ishikawa M; Nizato T; Suzuki K; Konno F
    J Med Chem; 1998 Jul; 41(16):3015-21. PubMed ID: 9685241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.
    Bromidge SM; Dabbs S; Davies DT; Duckworth DM; Forbes IT; Ham P; Jones GE; King FD; Saunders DV; Starr S; Thewlis KM; Wyman PA; Blaney FE; Naylor CB; Bailey F; Blackburn TP; Holland V; Kennett GA; Riley GJ; Wood MD
    J Med Chem; 1998 May; 41(10):1598-612. PubMed ID: 9572885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of S-21007, a potent 5-HT3 partial agonist, in mouse anxiety.
    Delagrange P; Misslin R; Seale TW; Pfeiffer B; Rault S; Renard P
    Zhongguo Yao Li Xue Bao; 1999 Sep; 20(9):805-12. PubMed ID: 11245088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and 5-HT3 affinity of new 3-substituted indoles at central nervous system.
    Monge A; Palop JA; Orts L; Oset C; Lasheras B
    Drug Des Discov; 1996 Oct; 14(2):157-70. PubMed ID: 9010621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
    Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies.
    Campiani G; Morelli E; Gemma S; Nacci V; Butini S; Hamon M; Novellino E; Greco G; Cagnotto A; Goegan M; Cervo L; Dalla Valle F; Fracasso C; Caccia S; Mennini T
    J Med Chem; 1999 Oct; 42(21):4362-79. PubMed ID: 10543880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.